A retrospective propensity-score-matched cohort study of the impact of procalcitonin testing on antibiotic use in hospitalized patients during the first wave of COVID-19
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkae246 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Jonathan A T Sandoe und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, The General Infirmary at Leeds, Leeds, UK. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Procalcitonin, COVID-19, Propensity Score. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Health and Care Research COVID Recovery & Learning, HCRW, Manchester NIHR Biomedical Research Centre.
Abstract (Originalsprache)
Background
Procalcitonin (PCT) is a blood marker used to help diagnose bacterial infections and guide antibiotic treatment. PCT testing was widely used/adopted during the COVID-19 pandemic in the UK.
Objectives
Primary: to measure the difference in length of early (during first 7 days) antibiotic prescribing between patients with COVID-19 who did/did not have baseline PCT testing during the first wave of the pandemic. Secondary: to measure differences in length of hospital/ICU stay, mortality, total days of antibiotic prescribing and resistant bacterial infections between these groups.
Methods
Multi-centre, retrospective, observational, cohort study using patient-level clinical data from acute hospital Trusts/Health Boards in England/Wales. Inclusion: patients ≥16 years, admitted to participating Trusts/Health Boards and with a confirmed positive COVID-19 test between 1 February 2020 and 30 June 2020.
Results
Data from 5960 patients were analysed: 1548 (26.0%) had a baseline PCT test and 4412 (74.0%) did not. Using propensity-score matching, baseline PCT testing was associated with an average reduction in early antibiotic prescribing of 0.43 days [95% confidence interval (CI): 0.22–0.64 days, P < 0.001) and of 0.72 days (95% CI: 0.06–1.38 days, P = 0.03] in total antibiotic prescribing. Baseline PCT testing was not associated with increased mortality or hospital/ICU length of stay or with the rate of antimicrobial-resistant secondary bacterial infections.
Conclusions
Baseline PCT testing appears to have been an effective antimicrobial stewardship tool early in the pandemic: it reduced antibiotic prescribing without evidence of harm. Our study highlights the need for embedded, rapid evaluations of infection diagnostics in the National Health Service so that even in challenging circumstances, introduction into clinical practice is supported by evidence for clinical utility. Study registration number ISRCTN66682918.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, The General Infirmary at Leeds, Leeds, UK.
- Healthcare Associated Infection Group, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
- Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK.
- Department of Infection Sciences, Southmead Hospital, North Bristol NHS Trust, Bristol, UK.
- Pharmacy Department, Mid Yorkshire Teaching NHS Trust, Wakefield, UK.
- Division of Immunology, Immunity to Infection and Respiratory Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
ORCID-Profile: Jonathan A T Sandoe, Detelina Grozeva, Stuart E Bond, Paul Dark, Joanne Euden, Philip Howard, David G Partridge, Neil Powell
Förderung
- National Institute of Health and Care Research COVID Recovery & Learning
- HCRW
- Manchester NIHR Biomedical Research Centre
- NIHR Senior Investigator Award
- Health and Care Research Wales
Zitieren
APA
Sandoe, J. A. T., Grozeva, D., Albur, M., Bond, S. E., Brookes-Howell, L., Dark, P., Euden, J., Hamilton, R., Hellyer, T. P., Henley, J., Hopkins, S., Howard, P., Howdon, D., Knox-Macaulay, C., Llewelyn, M. J., Maboshe, W., McCullagh, I. J., Ogden, M., Parsons, H. K., …, & Pallmann, P. (2024). A retrospective propensity-score-matched cohort study of the impact of procalcitonin testing on antibiotic use in hospitalized patients during the first wave of COVID-19. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae246
Vancouver
Sandoe JAT, Grozeva D, Albur M, Bond SE, Brookes-Howell L, Dark P, et al. A retrospective propensity-score-matched cohort study of the impact of procalcitonin testing on antibiotic use in hospitalized patients during the first wave of COVID-19. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae246
BibTeX
@article{Sandoe2024,
author = {Sandoe, Jonathan A T and Grozeva, Detelina and Albur, Mahableshwar and Bond, Stuart E and Brookes-Howell, Lucy and Dark, Paul and Euden, Joanne and Hamilton, Ryan and Hellyer, Thomas P and Henley, Josie and Hopkins, Susan and Howard, Philip and Howdon, Daniel and Knox-Macaulay, Chikezie and Llewelyn, Martin J and Maboshe, Wakunyambo and McCullagh, Iain J and Ogden, Margaret and Parsons, Helena K and Partridge, David G and Powell, Neil and Prestwich, Graham and Shaw, Dominick and Shinkins, Bethany and Szakmany, Tamas and Thomas-Jones, Emma and Todd, Stacy and West, Robert M and Carrol, Enitan D and Pallmann, Philip},
title = {A retrospective propensity-score-matched cohort study of the impact of procalcitonin testing on antibiotic use in hospitalized patients during the first wave of COVID-19},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkae246}
}
EUVIMED